A new study has found that the Crohn’s Disease Exclusion Diet (CDED), a novel whole-food based dietary approach, combined with Modulen IBD, a Nestlé Health Science nutritional supplement for partial enteral nutrition (PEN), is effective for the management of Crohn’s disease.
There is no cure for Crohn’s disease- a chronic condition that causes inflammation of the digestive system or gut. Most patients typically rely on anti-inflammatory drugs and surgical interventions to manage their symptoms, which can be expensive, for both the patient and health care providers. However, a randomized control trial, has shown that a nutrition-based approach, combining CDED and Modulen IBD is effective for the management and remission of Crohn’s disease.
Nestlé Health Science leveraged the results of the study to create ModuLife, a platform to support dietary management for patients with Crohn’s disease. Through ModuLife, patients benefit from the essential nutrients of Modulen IBD, while also enjoying whole foods and using an online platform to personalize and manage their diet through access to recipes and meals plans, diet tracking adherence, as well as guidance from CDED specialists.
Because ModuLife is physician-supervised, patients and their healthcare providers can easily collaborate to ensure that patients receive ongoing support and maintain habits that prolong the remission of their disease.
"ModuLife is a paradigm change for how Crohn’s disease patients and healthcare providers manage the disease," said Greg Behar, CEO of Nestlé Health Science. "It provides healthcare professionals with a dietary approach backed by science and it provides patients with support programs as they make the changes to their diet. It is an excellent example of Nestlé Health Science’s dedication to advancing the role of nutrition through science-based innovation."
Read the full press release